Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 232

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 232
---
 may require to develop or commercialize any of our drug candidates would have a material adverse impact on us.

<div align='center'>128</div>

Trademarks

As of the date hereof, we own
trademark registrations covering the trade names and logos of Aptorum and our subsidiaries, including but not limited to “APTORUM”,
“APTORUM THERAPEUTICS,” “VIDENS LIFE SCIENCES,” “ACTICULE LIFE SCIENCES,” “NATIVUS LIFE SCIENCES,”
“NativusWell,” “TALEM” in jurisdictions Hong Kong, EU and the United Kingdom and PRC. Furthermore, we
are in the process of applying for registration of trademarks in jurisdictions including the U.S., EU, the United Kingdom, Australia and
PRC.

We also own certain unregistered trademark
rights.

All other trade names, trademarks
and service marks of other companies appearing in this proxy statement/prospectus are the property of their respective holders. Solely
for convenience, the trademarks and trade names in this proxy statement/prospectus are referred to without the and
symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks and trade names to
imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Facilities

We have an operating lease
for laboratory in Hong Kong, with 2,021 square feet lab space under a lease that commenced in March 2020, renewed in March 2023
and expires in March 2026. The monthly rent ranges from $6,348 to $9,068. Payments under operating leases are expensed on a straight-line
basis over the periods of the respective leases, and the terms of the leases do not contain contingent rent and renewal or purchase options.

We believe our current facilities are
sufficient to meet our needs.

Legal Proceedings

The Company is party to a lawsuit
initially filed on notice on September 3, 2024, by Karen Cheung (“Plaintiff”) in the Supreme Court of the State of New York,
County of New York (“State Court Action”) (Index No. 654541/2024), which sought relief arising from (i) violations of the
federal Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 § U.S.C